Taiwan News5d
China 3D Cardiac Mapping Market Segments Analysis and Growth Opportunities
The China 3D cardiac mapping market has showcased significant growth, with its valuation increasing from $55.55 million in 2019 to a projected $150.59 million by 2027. This report offers a detailed ...
Cardiac Ablation Market To Reach $8.6 Billion, Globally, By 2033 At 9.9% CAGR: Allied Market Research
Cardiac Ablation market 2033. PORTLAND, IL, UNITED STATES, December 17, 2024 /EINPresswire / -- Allied Market Research published a report, titled, "Cardiac ...
SciELO17d
Predictive value of cardiac electrophysiological balance index for recurrent atrial fibrillation after ablation
10 atrial flutter, and 4 atrial tachycardia). Significant differences in hypersensitive C-reactive protein levels, QT, QRS, and cardiac electrophysiological balance index were observed between ...
WebMD18d
Inappropriate Sinus Tachycardia
What Is Inappropriate Sinus Tachycardia? Sinus tachycardia is when your body sends out electrical signals to make your heart beat faster. Hard exercise, anxiety, certain drugs, or a fever can ...
Healthline19d
Common Medications for Atrial Fibrillation (AFib)
Share on Pinterest Marc Tran/Stocksy United Atrial fibrillation (AFib) is the most common type of arrhythmia– an abnormal heart rhythm. According to the Centers for Disease Control and ...
Business Wire25d
U.S. FDA Approves AOP Health’s Rapiblyk™ (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting
“Rapiblyk TM approval in the US represents an important milestone for patients experiencing supraventricular tachycardia, including atrial fibrillation and atrial flutter, who need rapid and ...
Adelaide Now25d
Imricor performs first atrial flutter ablation at Swiss hospital
Imricor Medical Systems has conducted its first cardiac atrial flutter ablation in the brand-new purpose built iCMR lab at the Lausanne University Hospital in Switzerland. It is also the third ...
Business Wire26d
U.S. FDA Approves AOP Health’s Rapiblyk TM (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting
“Rapiblyk TM approval in the US represents an important milestone for patients experiencing supraventricular tachycardia, including atrial fibrillation and atrial flutter, who need rapid and ...